By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Cyberonics Inc. announced that it has been formally notified by the Food and Drug Administration (FDA) that a meeting of FDA's Neurological Devices Advisory Panel has been scheduled for June 15, 2004 to review Cyberonics' PMA-Supplement seeking approval to market the VNS Therapy System. According to Cyberonics, VNS is being proposed "as an adjunctive long-term treatment of chronic or recurrent depression for patients over the age of 18 who are experiencing a major depressive episode that . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Cyberonics Inc. announced that it has been formally notified by the Food and Drug Administration (FDA) that a meeting of FDA's Neurological Devices Advisory Panel has been scheduled for June 15, 2004 to review Cyberonics' PMA-Supplement seeking approval to market the VNS Therapy System. According to Cyberonics, VNS is being proposed "as an adjunctive long-term treatment of chronic or recurrent depression for patients over the age of 18 who are experiencing a major depressive episode that . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!